B: Anti-TB Drugs available for use in the Philippines under a programmatic setting

from MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS — MODULE C

Summary of important points

ANNEx B

Anti-TB Drugs available for use in the Philippines under a programmatic setting

Grouping Drugs (abbreviation)

Group 1 – First-line oral anti-TB agents Isoniazid (H), Rifampicin (R), Ethambutol (E); Pyrazinamide (Z) Group 2 – Injectable anti-TB agents Streptomycin (S); Kanamycin (Km); Amikacin (Am); Capreomycin (Cm)

Group 3 – Fluoroquinolones Ciprofloxacin (Cfx); Ofloxacin (Ofx); Levofloxacin (Lfx); Moxifloxacin (Mfx); Gatifloxacin (Gfx)

Group 4 – Oral bacteriostatic second-line anti-TB agents Group 5 – Anti-TB agents with unclear efficacy (not recommended by WHO for routine use in MDR-TB patients) Ethionamide (Eto); Prothionamide (Pto); Cycloserine (Cs); p-aminosalicylic acid (PAS)

Clofazimine (Cfz); Amoxicillin/Clavulanate (Amx/Clv); Clarithromycin (Clr); Linezolid (Lzd)

B: Anti-TB Drugs available for use in the Philippines under a programmatic setting

Next Article

Summary of important points

ANNEx B

Anti-TB Drugs available for use in the Philippines under a programmatic setting

Grouping Drugs (abbreviation)

More articles from this publication:

Summary of important points

to the Consilium using the Consiliumex

4 .6 Implement treatment decisions

4 .6 .6 If a patient’s DST results have changed from baseline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 4 .6 .7 Initiate counseling for possible treatment failure before terminating treatment

Exercise C: Written Exercise

Introduction

3 .5 Make referral to Treatment Center physician as necessary for moderate or severe ADRs

1 .3 Determine whether there are other special circumstances affected by the regimen

G: Monthly follow-up visit to the Treatment Center physician

This article is from:

MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS — MODULE C